Trial Profile
Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs AAV AQP1 (Primary)
- Indications Head and neck cancer; Squamous cell cancer; Xerostomia
- Focus Adverse reactions; Proof of concept
- Sponsors MeiraGTx
- 16 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2023 Planned number of patients changed from 36 to 21.
- 08 Jun 2023 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.